Prideapplication/xmlftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD014853/IPMS.msfftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD014853/IPMS1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD014853/IPMS2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/08/PXD014853/IPMS3.rawprimary200OKsanjeeva@iitb.ac.inShuvolina MukherjeeMass SpectrometryGel-based experimentBrain CancerHuman immunoprecipitation ms-mshttps://www.ebi.ac.uk/pride/archive/projects/PXD014853BrainEpithelial CellBrain tumor tissue lysates were precleared using Protein G beads(CST) post the conjugation of the Antibody with the beads, the conjugated complex was used as a 'bait' to capture potential interacting partners that would bind to ANXA2.PrideData was analysed using Proteome Discoverer 2.2, all three replicates were run using the same gradient of 60 minutes in the LC MS-MS.ProteomicsSANJEEVA SRIVASTAVAPARTIALPROFESSOR, PRINCIPLE INVESTIGATOR, PROTEOMICS LAB, BSBE, IIT BOMBAYHomo Sapiens (human)32974197 Mukherjee S, Biswas D, Gadre R, Jain P, Syed N, Stylianou J, Zeng Q, Mahadevan A, Epari S, Shetty P, Moiyadi A, Roy Ball G, Srivastava S. Comprehending Meningioma Signaling Cascades Using Multipronged Proteomics Approaches & Targeted Validation of Potential Markers. Front Oncol. 2020 10:1600 10.3389/fonc.2020.01600mukherjeeshuvolina@gmail.comLund UniversitySwedenMeningiomas are one of the most prevalent primary brain tumors. Our study aims to obtain mechanistic insights of meningioma pathobiology using mass spectrometry-based label-free quantitative proteome analysis to identifying druggable targets and perturbed pathways for therapeutic intervention. Label-free based proteomics study was done from peptide samples of 21 patients and 8 non-tumor controls which were followed up with Phosphoproteomics to identify the kinases and phosphorylated components of the perturbed pathways. <i>In silico</i> approaches revealed perturbations in extracellular matrix remodeling and associated cascades. To assess the extent of influence of Integrin and PI3K-Akt pathways, we used an Integrin Linked Kinase inhibitor on patient-derived meningioma cell line and performed a transcriptomic analysis of the components. Furthermore, we designed a Targeted proteomics assay which to the best of our knowledge for very first-time enables identification of peptides from 54 meningioma patients via SRM assay to validate the key proteins emerging from our study. This resulted in the identification of peptides from CLIC1, ES8L2, and AHNK many of which are receptors and kinases and are difficult to be characterized using conventional approaches. Furthermore, we were also able to monitor transitions for proteins like NEK9 and CKAP4 which have been reported to be associated with meningioma pathobiology. We believe, this study can aid in designing peptide-based validation assays for meningioma patients as well as IHC studies for clinical applications.Comprehending Meningioma Signaling Cascades Using Multipronged Proteomics Approaches & Targeted Validation of Potential Markers.Mukherjee Shuvolina S, Biswas Deeptarup D, Gadre Rucha R, Jain Pooja P, Syed Nelofer N, Stylianou Julianna J, Zeng Qingyu Q, Mahadevan Anita A, Epari Sridhar S, Shetty Prakash P, Moiyadi Aliasgar A, Roy Ball Graham G, Srivastava Sanjeeva SBrain, ZNF693, Brain Tumors, Primary Malignant Brain Neoplasms, PAP-IV, HEL-S-270, Neoplasms, Primary Brain Neoplasms, Cancer of Brain, Brain Neoplasms, Benign Neoplasm, Gene, protein, B-cell receptor complex, Tumor, protein-containing complex, Malignant, Brain Metastases, antibody, BCR complex, Recurrent Brain Tumors, INTRACRANIAL NEOPL, dJ734G22.1, Recurrent, Gene Products, ANX2L4, D4Ertd432e, tumour of brain, protein aggregate, immunoglobulin complex, tumour of the Brain, brain neoplasms, membrane bound, Tissue, Brain Malignant Neoplasms, Primary Brain Tumors, BC040081, Brain Tumor, Cal1h, CAS11, PRIMARY BRAIN NEOPL, neoplasm of brain, Brain Neoplasm, Primary Malignant Brain Tumors, Recurrent Brain Tumor, B-lymphocyte receptor complex, tumor of brain, NEOPL INTRACRANIAL, Tumors, Cancer, LPC2D, Intracranial Neoplasm, brain neoplasm, Malignant Brain Neoplasms, Malignant Neoplasm, Brain Benign Neoplasm, protein complex, Benign Brain Neoplasms, Proteins, Malignant Primary Brain Neoplasms, Primary, Primary Brain Neoplasm, NEOPL BRAIN, antibodies, Primary Brain Tumor, 2410019P08Rik, Benign, Brain Benign Neoplasms, native protein, AV096627, CAL1H, Brain Malignant Neoplasm, Protein, Neoplasm, Malignant Primary Brain Tumors, Brain Cancers, P36, simple tissue, Brain Metastase, Malignant Brain Neoplasm, LIP2., Intracranial Neoplasms, opsonin activity, Primary Malignant, brain neoplasm (disease), SRG, Cancer of the Brain, Benign Neoplasms, tumor of the Brain, ANX2, Brain Cancer, Malignant Neoplasms, Protein Gene Products, Intracranial, Gene Proteins, immunoglobulin, Cst, CST, neoplasm of the brain, B cell receptor accessory molecule complex, brain tumor, B lymphocyte receptor complex, B cell receptor activity, LPC2, Benign Brain Neoplasm, AW215814, brain tumourClear Cell, Parasagittal Meningioma, Intracranial Meningiomas, Sphenoid Wing Meningioma, Intraorbital, Hemangiopericytic, Wing Meningioma, intracranial meningioma, Angiomatous Meningiomas, Multiple Meningiomas, Multiple Meningioma, Cerebral Convexity Meningioma, supratentorial meningioma, Malignant, Microcystic, Sphenoid Wing Meningiomas, Sphenoid, Papillary Meningiomas, Angioblastic, Papillary Meningioma, Sphenoid Wing, Xanthomatous Meningioma, Secretory Meningiomas, Hemangioblastic Meningiomas, Olfactory Groove, Cerebral, Xanthomatous Meningiomas, Fibrous, Secretory Meningioma, Angioblastic Meningioma, Convexity Meningioma, primary meningeal tumor, Fibrous Meningiomas, primary meningeal tumour, Hemangioblastic, Posterior Fossa Meningioma, Clear Cell Meningioma, Transitional Meningiomas, Groove Meningiomas, Meningotheliomatous, Angiomatous Meningioma, Olfactory, Hemangiopericytic Meningioma, Xanthomatous, Microcystic Meningioma, Meningiomatoses, Olfactory Groove Meningiomas, Secretory, Intraorbital Meningiomas, Meningioma, Posterior Fossa, Transitional, meningioma, Peptidomics., meningothelial cell tumour, Spinal Meningiomas, Posterior Fossa Meningiomas, Benign Meningiomas, familial, Transitional Meningioma, meningothelial cell tumor, Angioblastic Meningiomas, Meningotheliomatous Meningioma, Clear Cell Meningiomas, Hemangioblastic Meningioma, Intraorbital Meningioma, Psammomatous Meningiomas, Benign, Intracranial Meningioma, Angiomatous, Parasagittal, Spinal Meningioma, Intraventricular Meningiomas, Meningotheliomatous Meningiomas, Olfactory Groove Meningioma, Malignant Meningiomas, MNGMA, Meningiomas, Intraventricular Meningioma, Microcystic Meningiomas, Meningiomatosis, susceptibility to, Cerebral Convexity Meningiomas, Convexity Meningiomas, Cerebral Convexity, Hemangiopericytic Meningiomas, Papillary, Intracranial, Psammomatous Meningioma, Multiple, Wing Meningiomas, susceptibility to familial meningioma, Psammomatous, Fibrous Meningioma, Parasagittal Meningiomas, Spinal, Benign Meningioma, meningeal neoplasm, Intraventricular, Malignant MeningiomaCG1849, l(1)LB9, NinaC, ninac, Runt, leg, Dm NinaC, DmelCG1849, NINA C, CG5125, l(1)19Ea, Rnt, AA33., CG 5125, DmelCG5125, P235, lLB5, l(1)AA33, Nina C, l(1)B2/13.1, RUN, Run, CT42491, 1, 2, 2.2, NINAC, CT16120, CG54125, LB5, DRONINACLipocortin II, LPC2D, PAP-IV, P36 Annexin II, annexin 2, HEL-S-270, sodium dodecyl sulphate–polyacrylamide gel electrophoresis., Calpactin I, Gel Electrophoresis, B-cell receptor complex, antibodies, SDS polyacrylamide gel electrophoresis of proteins, Capactin I Heavy Chain, ANNEXIN, antibody, Annexin II, Sodium Dodecyl Sulfate PAGE, BCR complex, CAL1H, Polyacrylamide Gel Electrophoresis, ANX2L4, SDS-PAGE, P36, immunoglobulin complex, LIP2, opsonin activity, MXK3.27, ANNEXIN A2, Polyacrylamide, PPI, SDS-PAGE electrophoresis, Sodium Dodecyl Sulfate-PAGE, membrane bound, SDS polyacrylamide gel electrophoresis, Cal1h, ANX2, Annexin A2, immunoglobulin, B cell receptor accessory molecule complex, B lymphocyte receptor complex, B cell receptor activity, LPC2, MXK3_27, AW215814, Sodium Dodecyl Sulfate-PAGEs, B-lymphocyte receptor complex, Runnings, P90 Complex, SDS PAGEClear Cell, PRKBA, dmBest1, Akt/PKB, dP60, intracranial meningioma, Vps34, DAKT1/PKB, Brain Neoplasms, BcDNA:LD15217, Multiple Meningioma, Tumor, AKT1, VPS34, Brain Metastases, 11621, DmelCG6264, Long Term, Sphenoid, PI-3 kinase, p110-alpha, Polypeptides, Papillary Meningiomas, Donor Artificial Insemination, Angioblastic, CDA2, Kinase, Analysis, alpha2Int, Extracellular Matrices, Dp60, primary meningeal tumor, Analyses, PI3K_59F, primary meningeal tumour, Brain Malignant Neoplasms, PI3-kinase activity, Brain Tumor, PI3Kgamma, SURGICAL AND MEDICAL PROCEDURES, Meningotheliomatous, RacPK, MCAP, DmelCG9623, Xanthomatous, Brain Neoplasm, scientific observation, PI3K 68D, ATP Phosphotransferases, ATP - 1-phosphatidyl-1D-myo-inositol 3-phosphotransferase activity, Tumors, meningioma, meningothelial cell tumour, dVps34, Intracranial Neoplasm, Malignant Brain Neoplasms, Brain Benign Neoplasm, Benign Meningiomas, rea, familial, Longterm Effect, p50alpha, Primary Brain Neoplasm, Procedure, Spectrum Analysis, CG2699, Clear Cell Meningiomas, DmelCG5373, Primary Brain Tumor, AKT/PKB, DmIKKgamma, Benign, C530050K14, dIKK, Brain Malignant Neoplasm, type-1 PI3K, Heterologous Insemination, Intraventricular Meningiomas, p-Akt, Meningotheliomatous Meningiomas, TU15B, Malignant Brain Neoplasm, Meningiomas, Primary Malignant, CG11621, G6, dbest1, IKK-gamma, Spectrometry, Convexity Meningiomas, Benign Neoplasms, dAKT/dPKB, PKB/dAKT, DmelCG4141, F8A5_4, Hemangiopericytic Meningiomas, Malignant Neoplasms, APDS, Papillary, Psammomatous Meningioma, Multiple, Artificial Insemination, label, PI3KBETA, Parasagittal Meningiomas, other neoplasm, RAC-ALPHA, Brain, 5630400A09Rik, Brain Tumors, DmelCG4006, nercc, Angiomatous Meningiomas, Peptidomics, Effects, Neoplasms, Cerebral Convexity Meningioma, supratentorial meningioma, AID, dIKK-gamma, Aid, PIK3, in, Recurrent Brain Tumors, dVps34/PI3K59F, Pi3Kp60, Papillary Meningioma, PI3K-dp110, DmIKK-gamma, nercc1, Gene Products, dPI3K, anon-92Ed, If, aid, class I, Insemination, interventionDescription, Longterm, Fibrous Meningiomas, VMD2, Hemangioblastic, Posterior Fossa Meningioma, BMD, Long-Term, Pi3Kp110, P110BETA, Nek8, Neoplasias, Angiomatous Meningioma, Hemangiopericytic Meningioma, PI3K21B, alphaPS2C, AKT, Akt, HEL-S-284, Extracellular, PS 2, kinase inhibitor, peptidos, MCM, NERCC1, Secretory, Intraorbital Meningiomas, SPS1, Heterologous, Cancer, Cpk, RP50, Transitional, measuring, Malignant Neoplasm, AA414921, akt, class II, type III phosphoinositide 3-kinase activity, Proteins, Transitional Meningioma, Meningotheliomatous Meningioma, DAkt1, Primary, DAKT1, PI(3)K, cpk, Human Donor, PI3K-92E/Dp110, polypeptide, IKKgamma, Psammomatous Meningiomas, PIK3C1, MS, PKB, Angiomatous, CWS6, Parasagittal, CWS5, Spinal Meningioma, chemical analysis, Long Term Effects, PKB-ALPHA, Neoplasm, CG4006, Donor, Malignant Meningiomas, Mass Spectrum Analyses, Intervention, Dakt1, Artificial, best, Intraventricular Meningioma, Dmikkgamma, Arp2, ARP2, Cancers, DmelCG11621, CG16910, Longterm Effects, Gene Proteins, caPI3K, dAkt/PKB, Psammomatous, CLOVE, DmVps34, IMD14, PI3K_68D, PI3K-92D, ERGIC-63, alpha[[PS2(ms8)]], Benign Meningioma, Benign Brain Neoplasm, Dmp110, Intraventricular, BEST, Neoplasia, Intracranial Meningiomas, Sphenoid Wing Meningioma, Intraorbital, Hemangiopericytic, Wing Meningioma, CG5373, alphaPS2, determination, ATVPS34, PI3K, Dp110, C130021H08Rik, Sphenoid Wing Meningiomas, peptide, PHOSPHATIDYLINOSITOL 3-KINASE, peptido, DmelCG2699, F8A5.4, ARB, p110alpha, phosphatidylinositol 3-kinase activity, Effect, IKKg, KEY, Key, Donor Artificial, Xanthomatous Meningiomas, Mass Spectrum Analysis, Fibrous, Angioblastic Meningioma, Convexity Meningioma, peptides, Pi3K92D, CG4141, catalyst activity, Clear Cell Meningioma, Primary Brain Tumors, Pi3k, Transitional Meningiomas, PI[[3]]K, PKB|Akt, p55alpha, Primary Malignant Brain Tumors, Recurrent Brain Tumor, Therapies, Meningiomatoses, Malignancies, Pi3K, PI3k, Olfactory Groove Meningiomas, MCMTC, Long-Term Effects, ATP, Meningioma, Therapy, PI3K68D, dakt, CG6264, P110DELTA, PtdIns-3-kinase activity, PS2, Malignant Primary Brain Neoplasms, Clcp, l(3)89Bq, SPDSY, vacuolar protein sorting 34, dPIK, 1-phosphatidylinositol 3-kinase activity, Multiple Reaction Monitoring, Spectroscopy, aPS2, Intraorbital Meningioma, CT27194, PKB/Akt, PKB/AKT, Brain Benign Neoplasms, dAkt, dAKT, inhibition of kinase activity, Kenny, Malignant Primary Brain Tumors, Olfactory Groove Meningioma, DAkt, MNGMA, l(3)04226, dBest1, Transphosphorylases, DPKB, Epistemology, pAkt, p85alpha, Cancer of the Brain, Microcystic Meningiomas, Meningiomatosis, susceptibility to, CG9623, PI3K 68_D, Treatments, Intracranial, p110D, Dakt, DmelCG16910, Fibrous Meningioma, Patient, dPKB, meningeal neoplasm, Polypeptide, p120-PI3K, Malignant Meningioma, PSalpha2, Proteomes, droPIK57, Parasagittal Meningioma, DRAC-PK85, Primary Malignant Brain Neoplasms, SRML1, P63, Primary Brain Neoplasms, Cancer of Brain, PI3K92E, Multiple Meningiomas, Benign Neoplasm, Matrix, Integrin, Pi3K_59F, Gene, Spectrum Analyses, Matrices, type I phosphatidylinositol kinase activity, anon-WO0118547.380, Malignant, CLIMP-63, Microcystic, phosphatidylinositol 3-kinase, Intervention or Procedure, Dpkb, Client., Sphenoid Wing, Recurrent, p60, p63, Xanthomatous Meningioma, Mass, PHOSPATIDYLINOSITOL 3-KINASE, Secretory Meningiomas, dmIKKgamma, Hemangioblastic Meningiomas, Olfactory Groove, IKK[[gamma]], Cerebral, Phosphotransferase, Mass Spectroscopy, Dp110/PI3K, PI3K-68D/E, Secretory Meningioma, study, matrisome, alpha[[PS2]], MRM, Malignancy, Interventional, Groove Meningiomas, PI3'K, Transphosphorylase, integrin, PI3K-68D, Olfactory, IKK, Clients, Microcystic Meningioma, DRAC-PK, NERCC, HIGM2, Long-Term Effect, Posterior Fossa, Intervention Strategies, dP110, 6330412C24Rik, Spinal Meningiomas, p120, Posterior Fossa Meningiomas, Benign Brain Neoplasms, PAPT, meningothelial cell tumor, total expressed protein, p110, Angioblastic Meningiomas, Vps34p, NCC27, Client, Peptide, Phosphotransferases, Hemangioblastic Meningioma, ATP:1-phosphatidyl-1D-myo-inositol 3-phosphotransferase activity, Intracranial Meningioma, vps34, Protein, dp110, Brain Cancers, D-Akt, PI3CG, Brain Metastase, Intracranial Neoplasms, PI-3-K, Mass Spectrum, PI3K-59F, Dbest, PI3K-Dp110, akt1, dAkt1, Kinases, DRAC-PK66, Cerebral Convexity Meningiomas, class III, patient, Cerebral Convexity, p110gamma, Brain Cancer, inf, Protein Gene Products, Wing Meningiomas, susceptibility to familial meningioma, dakt1, Therapeutic, PKBalpha, Spinal, PS2alpha, Treatment, Peptid, dAKT1, assay, RAC, RacClear Cell, Parasagittal Meningioma, Intracranial Meningiomas, Sphenoid Wing Meningioma, Intraorbital, Hemangiopericytic, Wing Meningioma, intracranial meningioma, Angiomatous Meningiomas, Multiple Meningiomas, Multiple Meningioma, Cerebral Convexity Meningioma, supratentorial meningioma, Malignant, Microcystic, Sphenoid Wing Meningiomas, Sphenoid, Papillary Meningiomas, Angioblastic, Papillary Meningioma, Sphenoid Wing, Xanthomatous Meningioma, Secretory Meningiomas, Hemangioblastic Meningiomas, Olfactory Groove, Cerebral, Xanthomatous Meningiomas, Fibrous, Secretory Meningioma, Angioblastic Meningioma, Convexity Meningioma, primary meningeal tumor, Fibrous Meningiomas, primary meningeal tumour, Hemangioblastic, Posterior Fossa Meningioma, Clear Cell Meningioma, Transitional Meningiomas, Groove Meningiomas, Meningotheliomatous, Angiomatous Meningioma, Olfactory, Hemangiopericytic Meningioma, Xanthomatous, Microcystic Meningioma, Meningiomatoses, Olfactory Groove Meningiomas, Secretory, Intraorbital Meningiomas, Meningioma, Posterior Fossa, single organism signaling, Transitional, meningioma, Peptidomics., meningothelial cell tumour, Spinal Meningiomas, Posterior Fossa Meningiomas, Benign Meningiomas, familial, Transitional Meningioma, meningothelial cell tumor, Angioblastic Meningiomas, Meningotheliomatous Meningioma, Clear Cell Meningiomas, Hemangioblastic Meningioma, Intraorbital Meningioma, Psammomatous Meningiomas, Benign, Intracranial Meningioma, Angiomatous, Parasagittal, Spinal Meningioma, Intraventricular Meningiomas, Meningotheliomatous Meningiomas, Olfactory Groove Meningioma, Malignant Meningiomas, MNGMA, Meningiomas, Intraventricular Meningioma, Microcystic Meningiomas, Meningiomatosis, susceptibility to, Cerebral Convexity Meningiomas, Convexity Meningiomas, Cerebral Convexity, Hemangiopericytic Meningiomas, Papillary, Intracranial, Psammomatous Meningioma, Multiple, Wing Meningiomas, susceptibility to familial meningioma, Psammomatous, Fibrous Meningioma, signalling process, Parasagittal Meningiomas, Spinal, Benign Meningioma, meningeal neoplasm, Intraventricular, Malignant MeningiomafalseMining Meningioma Proteomics Alterations Using IP MSHerein we have used IP-MS based approach to identify potential interactors (PPI) that bind to Annexin A2. We have used Immunoaffinity based enrichment using antibody specific to ANXA2 followed by LC MS-MS of the Complex post running it in SDS-PAGE2021-08-302019-07-31PXD014853NEWT:3555NEWT:71647NEWT:35554NEWT:32046NEWT:544496NEWT:2042546NEWT:32049NEWT:1392696NEWT:259447NEWT:295546NEWT:45351NEWT:445974NEWT:43179NEWT:180454NEWT:5722NCBITaxon:1280NEWT:1129NEWT:309807NEWT:55153NEWT:309800NEWT:281395NEWT:1211601NEWT:876138NEWT:44271NEWT:10036NEWT:1590NEWT:498019NEWT:1351NEWT:1438992NEWT:1352NEWT:2649997NEWT:1147161NEWT:263737NEWT:224326NEWT:1333499NCBITaxon:79857NEWT:1096976NEWT:95648NEWT:1589NEWT:135622NEWT:1349NEWT:96731NEWT:383379NEWT:10029NEWT:913645NEWT:44491NEWT:556484NEWT:317447NEWT:4688NEWT:7955NEWT:7959NEWT:2261NEWT:31156NEWT:3112NEWT:4442NEWT:192875NEWT:1214915NEWT:12637NEWT:59729NEWT:2164133NEWT:108061NEWT:1316931NEWT:224308NEWT:3347NEWT:511145NEWT:931281NEWT:658457NEWT:1310161NEWT:77133NEWT:295358NEWT:145481NCBITaxon:79824NEWT:2246NCBITaxon:4563NEWT:5755NEWT:44689NEWT:44447NEWT:498211NEWT:5759NEWT:1736231NEWT:5518NEWT:398007NEWT:1392NEWT:498217NEWT:498216NEWT:2242NEWT:11320NEWT:286NEWT:391619NEWT:246196NEWT:287NEWT:246197NEWT:633149NEWT:10239NEWT:44685NEWT:161934NEWT:1148NEWT:5508NEWT:5507NEWT:410661NEWT:55571NEWT:35500NEWT:1140NCBITaxon:2157NEWT:1143NEWT:4896NEWT:1390NEWT:11557NEWT:1094343NEWT:1336795NEWT:644042NEWT:294NEWT:1773NEWT:1182590NEWT:3712NEWT:82380NEWT:935293NEWT:375146NEWT:118698NEWT:1616117NEWT:263NEWT:118696NEWT:52283NEWT:284812NEWT:8175NEWT:43330NEWT:1603293NEWT:408169NEWT:44664NEWT:47946NEWT:3702NEWT:243277NEWT:7067NEWT:118694NEWT:2850NEWT:118691NEWT:33548NEWT:274NEWT:408172NEWT:408170NEWT:96794NEWT:3708NEWT:332648NEWT:44670NEWT:536231NEWT:376219NEWT:1436733NEWT:460519NEWT:1247411NEWT:572307NEWT:1432138NEWT:1424507NEWT:1194599NEWT:272844NEWT:9483NEWT:333760NEWT:1513458NCBITaxon:40559NEWT:506599NEWT:84588NEWT:1679718NEWT:480NEWT:67767NEWT:46835NEWT:109757NEWT:582580NEWT:300852NEWT:1502NEWT:376686NEWT:95486NEWT:508771NEWT:1883446NEWT:253NCBITaxon:2759NEWT:1233435NEWT:93061NEWT:93062NCBITaxon:4932NEWT:644223NEWT:235443NEWT:108458NEWT:272623NEWT:272624NEWT:320637NEWT:983964NEWT:118499NEWT:32644NEWT:527796NEWT:499175NEWT:109779NEWT:3745NEWT:1715989NCBITaxon:4751NEWT:476272NEWT:3747NEWT:195051NEWT:3988NEWT:1255228NEWT:649908NEWT:410289NEWT:373153NEWT:3983NEWT:352472NEWT:1071661NEWT:360094NEWT:470NEWT:41364NEWT:1313NEWT:39491NCBITaxon:5811NEWT:29491NEWT:2014887NEWT:33952NEWT:261756NEWT:571256NEWT:40483NEWT:272634NEWT:9031NEWT:1872122NEWT:7091NEWT:141262NEWT:108931NEWT:1055524NEWT:4087NEWT:9778NEWT:306NEWT:150475NEWT:303NEWT:267872NEWT:7111NEWT:347515NEWT:9534NEWT:5180NEWT:256737NEWT:4090NEWT:4092NEWT:9541NEWT:8694NEWT:4093NEWT:4096NEWT:8692NEWT:185579NEWT:941442NEWT:13076NEWT:1226408NEWT:7108NEWT:40479NEWT:4076NEWT:317NEWT:1006581NEWT:885318NEWT:39488NEWT:550NEWT:4081NEWT:273068NEWT:554NEWT:98334NEWT:451516NEWT:4084NEWT:63577NEWT:36185NEWT:1225786NEWT:7574NEWT:1715256NEWT:30640NEWT:575412NEWT:929793NEWT:29204NEWT:28112NEWT:114155NEWT:6494NEWT:6491NEWT:507601NEWT:186441NEWT:643680NEWT:214092NCBITaxon:6157NEWT:6239NEWT:162425NEWT:216257NEWT:102169NEWT:9986NEWT:4054NEWT:8654NEWT:8658NEWT:1268063NEWT:8655NEWT:1263854NEWT:118503NEWT:2059687NEWT:160488NEWT:28104NEWT:407821NCBITaxon:2NEWT:985076NEWT:1215323NEWT:986NEWT:52641NEWT:7159NEWT:28532NEWT:353152NEWT:8496NEWT:27448NEWT:40674NEWT:1194669NEWT:51329NEWT:243230NEWT:1080772NEWT:519NEWT:8479NEWT:8485NEWT:6063NEWT:49240NEWT:104395NEWT:6289NEWT:6287NEWT:300641NEWT:727NEWT:9796NEWT:725NEWT:469008NEWT:256318NEWT:9321NEWT:206411NCBITaxon:6191NEWT:596153NEWT:229533NEWT:1836NEWT:214053NEWT:80863NEWT:105231NEWT:52638NEWT:57075NEWT:4097NEWT:8697NEWT:8695NEWT:884204NEWT:9785NEWT:6279NEWT:1123869NEWT:9544NEWT:7370NEWT:83906NCBITaxon:780NCBITaxon:1502NEWT:6282NEWT:1134506NEWT:38783NEWT:4006NEWT:6426NCBITaxon:5476NEWT:6669NEWT:9935NEWT:89453NEWT:287889NEWT:51515NEWT:588596NEWT:51511NEWT:8845NEWT:92867NEWT:92866NEWT:5334NEWT:51750NEWT:202950NEWT:382352NEWT:413071NCBITaxon:714NEWT:295027NEWT:632957NEWT:9925NEWT:89462NCBITaxon:9606NEWT:8839NEWT:90690NEWT:4232NEWT:2758385NEWT:11298NEWT:171101NEWT:714NEWT:421932NEWT:312017NEWT:196627NEWT:200308NEWT:553470NEWT:200302NEWT:870435NEWT:284593NEWT:100392NEWT:5315NEWT:9913NEWT:265872NEWT:105841NEWT:337330NEWT:2666255NEWT:2285NEWT:999810NCBITaxon:5693NEWT:1392998NEWT:380394NEWT:981087NEWT:180066NEWT:226900NEWT:231490NEWT:7725NEWT:430615NEWT:563041NEWT:326423NEWT:452467NEWT:198822NEWT:36111NEWT:326424NEWT:1416333NEWT:1678078NEWT:749906NEWT:418985NEWT:1817808NEWT:749907NEWT:145263NEWT:694569NEWT:27606NEWT:9739NEWT:59202NEWT:9975NEWT:8643NEWT:51953NEWT:3197NEWT:860688NEWT:13443NEWT:8644NEWT:36329NEWT:62615NCBITaxon:3044782NEWT:160235NEWT:72407NEWT:8639NEWT:349741NEWT:409859NEWT:157295NEWT:2096NEWT:192222NEWT:9721NEWT:137221NEWT:9963NEWT:1617910NEWT:565050NEWT:409860NEWT:2785785NEWT:411901NEWT:8626NEWT:105884NCBITaxon:9615NEWT:8621NEWT:58334NEWT:1193501NEWT:58331NEWT:6689NEWT:8624NEWT:5116NEWT:8623NEWT:298315NEWT:8618NEWT:70448NEWT:698936NEWT:9940NEWT:3168NEWT:1247190NEWT:521001NEWT:192011NEWT:1813887NEWT:118702NEWT:118700NEWT:224911NEWT:118705NCBITaxon:11552NEWT:334249NEWT:6945NEWT:184922NEWT:6703NEWT:2104NEWT:6943NEWT:2NEWT:157546NEWT:474186NEWT:38942NEWT:1493NEWT:307972NEWT:1496NEWT:2102NEWT:660469NEWT:45474NEWT:1590841NEWT:2282334NEWT:4513NEWT:1247NEWT:70667NEWT:6938NEWT:376741NCBITaxon:10407NEWT:1736309NEWT:4751NEWT:10360NEWT:47664NEWT:317548NEWT:15819NEWT:3654NEWT:237561NEWT:5833NEWT:6928NEWT:1239NEWT:36745NEWT:400727NEWT:272563NEWT:82688NEWT:3885NEWT:3888NEWT:5821NEWT:44139NCBITaxon:4896NEWT:6915NEWT:3649NEWT:101510NEWT:28903NEWT:3880NEWT:272559NEWT:28909NEWT:515849NEWT:3641NEWT:466585NEWT:1000589NEWT:85963NEWT:85962NEWT:143361NEWT:12993NEWT:398580NEWT:4565NEWT:1264690NEWT:515619NEWT:1299NEWT:34305NCBITaxon:183674NEWT:167387NEWT:84645NEWT:44586NEWT:1123294NEWT:626528NEWT:139927NEWT:4558NEWT:209285NEWT:5888NEWT:211586NEWT:747078NEWT:1282NEWT:1283NEWT:431241NEWT:4550NEWT:1000561NEWT:2133NEWT:4555NEWT:294381NEWT:197NEWT:1390363NEWT:35889NEWT:288705NEWT:29176NEWT:4787NEWT:3217NEWT:4547NEWT:3218NEWT:556182NEWT:1270NEWT:374990NEWT:1432059NEWT:156471NEWT:4784NEWT:360106NEWT:156476NEWT:4543NEWT:4785NEWT:360104NEWT:10117NEWT:10116NEWT:1280NEWT:10358NEWT:1735272NEWT:83334NEWT:83332NEWT:317513NEWT:580240NEWT:294128NEWT:11676NEWT:100226NEWT:4530NEWT:75058NEWT:13616NEWT:172NEWT:296543NEWT:173NEWT:316435NEWT:42157NEWT:1895NEWT:1034304NEWT:105023NEWT:866628NEWT:215358NEWT:64152NEWT:4924NEWT:749200NEWT:9378NEWT:990346NEWT:145953NEWT:257309NEWT:100816NEWT:230741NCBITaxon:1313NEWT:44544NEWT:4911NEWT:645463NEWT:129249NEWT:1077286NEWT:943129NEWT:990119NEWT:77216NEWT:1111708NEWT:227321NEWT:493760NEWT:106590NEWT:260710NEWT:257313NEWT:3827NEWT:400772NEWT:128161NEWT:930945NEWT:106592NEWT:46704NEWT:1187947NEWT:269796NEWT:10312NCBITaxon:1773NEWT:54571NEWT:9598NEWT:8030NEWT:1423772NEWT:1639NEWT:188229NEWT:3818NEWT:4909NEWT:759272NEWT:432359NEWT:1182263NEWT:943146NEWT:2711NEWT:537457NEWT:9103NEWT:715877NEWT:862238NEWT:29159NEWT:10306NEWT:8022NEWT:145943NEWT:595536NEWT:240906NEWT:593117NEWT:89920NEWT:29158NEWT:3633NEWT:3635NEWT:5811NEWT:180923NEWT:1328881NEWT:411483NEWT:76336NEWT:884019NEWT:198215NEWT:411490NEWT:200298NEWT:169963NEWT:225117NEWT:746128NEWT:43665NEWT:1266464NEWT:367830NEWT:178616NEWT:375451NEWT:357NEWT:9172NEWT:106178NEWT:411469NEWT:84023NEWT:1679NEWT:559292NEWT:411464NEWT:411460NEWT:2762NEWT:1174673NEWT:1328426NEWT:562NEWT:411470NEWT:2094720NCBITaxon:2697049NCBITaxon:138NEWT:28038NEWT:1663NEWT:62141NEWT:1423NEWT:4932NEWT:3603NEWT:2759NEWT:3848NEWT:3847NEWT:38293NEWT:1428NEWT:339NEWT:327159NEWT:178876NEWT:1660NEWT:327160NEWT:573NEWT:571NEWT:241368NEWT:42528NEWT:2664373NEWT:190802NEWT:9417NEWT:1216979NEWT:7237NEWT:115104NEWT:1121114NEWT:663NEWT:1081927NEWT:1238993NEWT:67825NEWT:187878NEWT:220668NEWT:1821314NEWT:1249668NEWT:426430NEWT:9407NEWT:9646NEWT:5286NEWT:7227NEWT:7469NEWT:9402NEWT:9644NEWT:415540NEWT:675060NEWT:334542NEWT:313625NEWT:27592NEWT:426428NEWT:227289NEWT:63459NEWT:1276815NEWT:588858NEWT:9638NEWT:9639NCBITaxon:11071NEWT:242231NEWT:197221NEWT:7215NEWT:2172103NCBITaxon:59201NEWT:7460NEWT:504457NEWT:434271NEWT:747679NEWT:66712NEWT:42752NEWT:746360NEWT:89764NEWT:470150NEWT:543734NEWT:73239NEWT:38018NEWT:226186NEWT:9870NEWT:8782NEWT:115357NEWT:435590NEWT:1902NEWT:1908NEWT:13164NEWT:216129NEWT:2664179NEWT:623NEWT:7038NEWT:6192NCBITaxon:38727NEWT:2829NEWT:366581NEWT:216599NEWT:216595NEWT:40559NEWT:9689NEWT:8355NEWT:633NEWT:9685NEWT:7029NEWT:1283300NEWT:9694NEWT:186990NEWT:632NEWT:6183NEWT:99586NEWT:630NEWT:334747NEWT:61235NEWT:343691NEWT:15368NEWT:1491466NEWT:436486NEWT:51655NEWT:170187NEWT:260707NEWT:8595NEWT:186763NEWT:185431NEWT:29760NEWT:260704NEWT:1719NEWT:703612NEWT:260705NEWT:692672NEWT:2697049NEWT:1216981NEWT:1109443NEWT:1249885NEWT:7004NEWT:9669NCBITaxon:6073NEWT:1089448NEWT:1415167NEWT:1329349NEWT:607699NEWT:208963NEWT:208964NEWT:27337NEWT:575584NEWT:3039NEWT:8727NEWT:8726NEWT:10090NEWT:4120NEWT:5693NEWT:2186NEWT:8724NEWT:8723NEWT:283166NEWT:37334NCBITaxon:10357NCBITaxon:10359NEWT:1203258NEWT:242619NEWT:49317NEWT:160791NEWT:34073NEWT:696811NEWT:373995NEWT:5689NEWT:544404NEWT:37349NEWT:4113NEWT:837NEWT:36015NEWT:81866NEWT:5691NEWT:48479NEWT:61435NEWT:627025NEWT:1097677NEWT:375939NEWT:61674NEWT:1117957NEWT:6526NEWT:8709NEWT:4100NEWT:1159556NEWT:5671NEWT:1076NEWT:4102NEWT:4101NEWT:6763NEWT:8700NEWT:803NEWT:29722NEWT:1692259NEWT:1486917NEWT:419947NEWT:468911NEWT:817NEWT:7604NEWT:818NEWT:135588NEWT:1843183NEWT:5661NEWT:51866NEWT:29719NEWT:58002NEWT:5665NEWT:6997NEWT:452589NEWT:4577NEWT:813NEWT:5664NEWT:2157NEWT:146479NEWT:1042986NEWT:1911079NEWT:69373NEWT:206189NEWT:264203NEWT:1480154NEWT:1274414NEWT:9612NEWT:38626NEWT:38865NEWT:3077NEWT:9615NEWT:10299NEWT:6100NEWT:112273NEWT:1147787NEWT:1440772NEWT:1355477NEWT:9605NEWT:9606NEWT:90371NEWT:641501NEWT:4153NEWT:278839NEWT:7668NEWT:915099NEWT:74940NEWT:13551NEWT:10041NEWT:9600NEWT:1450511NEWT:1143193NEWT:174934NEWT:179392NEWT:2823525NEWT:9838NEWT:9839NEWT:546414NEWT:3055NEWT:11167NEWT:4146NEWT:5478NEWT:6326NEWT:5476NEWT:1450520NEWT:1042311NEWT:299767NEWT:28835NEWT:1274432NEWT:2053667NEWT:1274426NEWT:9825NEWT:1274423NEWT:393765NEWT:39946NEWT:9823NEWT:95602NEWT:8732NEWT:314539NEWT:39947NEWT:718274NEWT:1274420NEWT:578458329741970000-0002-2005-5274